Sangamo Therapeutics: A Biotech at the Crossroads of Science and Survival

Sangamo Therapeutics faces a pivotal week: scientific breakthroughs in gene therapy and regulatory progress contrast with a Nasdaq delisting, 83% stock decline, and tight liquidity ahead of Q1 earnings.

The week ahead for Sangamo Therapeutics reads like a tale of two companies. On one side, there is the scientific promise of gene-editing breakthroughs and regulatory progress. On the other, a stark financial reality that has already forced the biotech off the Nasdaq and into the less regulated OTCQB Venture Market.

The stock’s departure from the technology exchange on May 5 was triggered by a prolonged slide below the $1 threshold. Over the past year, Sangamo’s shares have shed roughly 83% of their value, dragging the company’s market capitalization down to approximately $75 million. Yet, in a dramatic twist, the stock surged 31.5% on the very day of the delisting, with trading volume exploding to nearly 93 million shares — more than ten times the daily average. That initial euphoria has since cooled, and the shares have settled back to around $0.13, a far cry from the 52-week high of $0.77.

Scientific Progress Amid Financial Strain

While the stock has been under pressure, Sangamo’s research engine continues to hum. The company is presenting its latest findings at the annual meeting of the American Society of Gene & Cell Therapy in Boston, where its zinc-finger technology for treating chronic pain is taking center stage. Particular attention is being paid to the MINT platform, which aims to precisely integrate large DNA sequences into the genome — a capability that could open new frontiers in gene therapy.

On the regulatory front, Sangamo is making headway with its Fabry disease candidate, ST-920. The company is currently rolling out a phased submission of its biologics license application to the FDA. Another program targeting neuropathy has already secured Fast-Track designation from regulators, a status that can accelerate development and review.

The Numbers Game

The financial picture, however, remains a source of deep investor anxiety. On May 11, Sangamo will release its first-quarter results, and the numbers are expected to be tight. Analysts are forecasting earnings of just $0.005 per share on revenue of roughly $34 million. The balance sheet is burdened by negative working capital of $6.6 million, and liquidity remains the single biggest concern.

A capital raise in February brought in around $25 million, providing a lifeline for ongoing studies. But after a significant impairment charge in the fourth quarter of 2025, the company’s cash runway will be the focal point of the earnings call scheduled for 6:30 p.m. ET on May 11.

Strategic Options on the Table

Management is not sitting idle. A global investment bank has been engaged to evaluate all strategic alternatives for value creation, while the company simultaneously pursues new partnerships and licensing deals. Sangamo has said it will only disclose details once definitive agreements are reached.

The short-sellers are circling. Short interest rose 14% in early May, and analysts have recalibrated their expectations. One investment bank slashed its price target from $5.00 to $1.00, reflecting the harsh new reality of the OTC market.

A Pivotal Moment

The confluence of events on May 11 will be decisive. Either the clinical data from the MINT platform convinces new partners to step in, or the financial pressure will force painful cuts. For investors, the earnings call will provide the clearest picture yet of how much time Sangamo has left to turn scientific promise into financial stability.